Published in Arthritis Res Ther on March 18, 2004
The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int (2010) 3.67
Use of relative and absolute effect measures in reporting health inequalities: structured review. BMJ (2012) 2.23
The case for randomized controlled trials to assess the impact of clinical information systems. J Am Med Inform Assoc (2011) 1.42
New treatments compared to established treatments in randomized trials. Cochrane Database Syst Rev (2012) 1.28
Association of trial registration with the results and conclusions of published trials of new oncology drugs. Trials (2009) 1.19
Financial considerations in the conduct of multi-centre randomised controlled trials: evidence from a qualitative study. Trials (2006) 1.15
Treatment success in cancer: industry compared to publicly sponsored randomized controlled trials. PLoS One (2013) 1.03
A surplus of positive trials: weighing biases and reconsidering equipoise. Arthritis Res Ther (2004) 0.95
Should desperate volunteers be included in randomised controlled trials? J Med Ethics (2006) 0.88
When is it rational to participate in a clinical trial? A game theory approach incorporating trust, regret and guilt. BMC Med Res Methodol (2012) 0.86
Clinical equipoise and personal equipoise: two necessary ingredients for reducing bias in manual therapy trials. J Man Manip Ther (2011) 0.85
Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design. J Neurol (2011) 0.83
A survey of orthopaedic journal editors determining the criteria of manuscript selection for publication. J Orthop Surg Res (2011) 0.83
Challenges and successes of recruitment in the "angiotensin-converting enzyme inhibition in infants with single ventricle trial" of the Pediatric Heart Network. Cardiol Young (2012) 0.81
OARSI Clinical Trials Recommendations: Design and conduct of clinical trials of surgical interventions for osteoarthritis. Osteoarthritis Cartilage (2015) 0.80
The myth of equipoise in phase 1 clinical trials. Medscape J Med (2008) 0.80
Randomised trials in context: practical problems and social aspects of evidence-based medicine and policy. Trials (2015) 0.80
Non-steroidal anti-inflammatory drugs after hip replacement. BMJ (2006) 0.79
Ethics of randomised controlled trials--not yet time to give up on equipoise. Arthritis Res Ther (2004) 0.77
The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis. BMJ Open (2014) 0.76
More ethical and more efficient clinical research: multiplex trial design. BMC Res Notes (2014) 0.75
Equipoise, design bias and randomized controlled trials: the elusive ethics of new drugs--a comment. Arthritis Res Ther (2004) 0.75
Equipoise and the technology curve: Relevance in the design of Surgical trials. Bone Joint Res (2016) 0.75
Randomized controlled trials - a matter of design. Neuropsychiatr Dis Treat (2016) 0.75
Effects of persisting emotional impact from child abuse and norepinephrine transporter genetic variation on antidepressant efficacy in major depression: a pilot study. Clin Psychopharmacol Neurosci (2015) 0.75
Equipoise and the ethics of clinical research. N Engl J Med (1987) 17.24
Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA (2003) 16.08
Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA (1992) 10.84
The continuing unethical conduct of underpowered clinical trials. JAMA (2002) 10.34
Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability. BMJ (1996) 8.77
Association of funding and conclusions in randomized drug trials: a reflection of treatment effect or adverse events? JAMA (2003) 8.21
The uncertainty principle and industry-sponsored research. Lancet (2000) 7.75
Shared decision making and the concept of equipoise: the competences of involving patients in healthcare choices. Br J Gen Pract (2000) 6.46
A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. Arch Intern Med (1994) 5.04
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42
Publication bias in editorial decision making. JAMA (2002) 3.52
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Ethics of clinical trials from a bayesian and decision analytic perspective: whose equipoise is it anyway? BMJ (2003) 3.21
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Control Clin Trials (2003) 2.70
At what level of collective equipoise does a clinical trial become ethical? J Med Ethics (1991) 2.66
Industry-sponsored clinical research: a double-edged sword. Lancet (2001) 2.45
Can unequal be more fair? Ethics, subject allocation, and randomised clinical trials. J Med Ethics (1998) 2.22
Acknowledgment of uncertainty: a fundamental means to ensure scientific and ethical validity in clinical research. Curr Oncol Rep (2001) 2.09
The ethics of the randomized clinical trial. N Engl J Med (1982) 2.04
Randomisation and resource allocation: a missed opportunity for evaluating health care and social interventions. J Med Ethics (2000) 2.01
Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 1.79
The use of equipoise in clinical trials. Soc Sci Med (1998) 1.63
Community equipoise and the architecture of clinical research. Camb Q Healthc Ethics (1997) 1.61
Community-equipoise and the ethics of randomized clinical trials. Bioethics (1995) 1.56
Informed consent may be hazardous to health. Science (1979) 1.48
Equipoise as a means of managing uncertainty: personal, communal and proxy. J Med Ethics (1996) 1.47
Equipoise, knowledge and ethics in clinical research and practice. Bioethics (1999) 1.46
Quantifying and documenting prior beliefs in clinical trials. Stat Med (2001) 1.39
The Nuremberg Code: Hippocratic ethics and human rights. Lancet (1998) 1.13
Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med (2005) 2.98
Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol (2009) 2.39
Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med (2012) 2.19
Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis. Arthritis Rheum (2003) 1.62
Poor outcomes after acute myocardial infarction in systemic lupus erythematosus. J Rheumatol (2009) 1.58
Factors associated with patients who leave acute-care hospitals against medical advice. Am J Public Health (2007) 1.56
Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum (2003) 1.47
Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory. Arthritis Res Ther (2011) 1.44
Disease-related and all-cause health care costs of elderly patients with gout. J Manag Care Pharm (2008) 1.42
Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum (2010) 1.42
Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum (2006) 1.36
Lifestyle risk factors predict disability and death in healthy aging adults. Am J Med (2012) 1.27
The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). Arthritis Care Res (Hoboken) (2011) 1.22
Big data and clinicians: a review on the state of the science. JMIR Med Inform (2014) 1.17
Patient questionnaires and formal education level as prospective predictors of mortality over 10 years in 97% of 1416 patients with rheumatoid arthritis from 15 United States private practices. J Rheumatol (2004) 1.17
The PROMIS of better outcome assessment: responsiveness, floor and ceiling effects, and Internet administration. J Rheumatol (2011) 1.14
Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum (2013) 1.12
Muscle strength, mass, and quality in older men and women with knee osteoarthritis. Arthritis Care Res (Hoboken) (2012) 1.10
Upper-extremity and mobility subdomains from the Patient-Reported Outcomes Measurement Information System (PROMIS) adult physical functioning item bank. Arch Phys Med Rehabil (2013) 1.09
The components of action planning and their associations with behavior and health outcomes. Chronic Illn (2013) 1.07
Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J Rheumatol (2009) 1.05
Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis (2013) 1.04
Items, Instruments, Crosswalks, and PROMIS. J Rheumatol (2009) 0.98
Serum uric acid level and risk for peripheral arterial disease: analysis of data from the multiple risk factor intervention trial. Angiology (2007) 0.95
Trends in physician diagnosed gout and gout therapies in the US: results from the national ambulatory health care surveys 1993 to 2009. Arthritis Res Ther (2013) 0.95
A randomized, controlled trial of interferon-beta-1a (Avonex(R)) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Res Ther (2003) 0.94
Chronic kidney disease in gout in a managed care setting. BMC Nephrol (2011) 0.93
Development and assessment of floor and ceiling items for the PROMIS physical function item bank. Arthritis Res Ther (2013) 0.91
Exercise behavior of ultramarathon runners: baseline findings from the ULTRA study. J Strength Cond Res (2013) 0.90
Dutch translation and cross-cultural adaptation of the PROMIS® physical function item bank and cognitive pre-test in Dutch arthritis patients. Arthritis Res Ther (2012) 0.88
Systemic lupus erythematosus, rheumatoid arthritis, and postarthroplasty mortality: a cross-sectional analysis from the nationwide inpatient sample. J Rheumatol (2010) 0.87
Relationship between physician specialty and allopurinol prescribing patterns: a study of patients with gout in managed care settings. Curr Med Res Opin (2011) 0.84
Extending the floor and the ceiling for assessment of physical function. Arthritis Rheumatol (2014) 0.83
Sleep-disordered breathing among women with fibromyalgia syndrome. J Clin Rheumatol (2006) 0.82
What constitutes progress in assessing patient outcomes? J Clin Epidemiol (2009) 0.81
An analysis of connective tissue disease-associated interstitial lung disease at a US Tertiary Care Center: better survival in patients with systemic sclerosis. J Rheumatol (2011) 0.81
Relative performance of commonly used physical function questionnaires in rheumatoid arthritis and a patient-reported outcomes measurement information system computerized adaptive test. Arthritis Rheumatol (2014) 0.80
Atherosclerotic cardiovascular disease and dermatomyositis: an analysis of the Nationwide Inpatient Sample survey. Arthritis Res Ther (2013) 0.79
Body mass index and its correlates in 1,212 ultramarathon runners: baseline findings from the ULTRA study. J Phys Act Health (2013) 0.78
Rheumatoid arthritis: radiographic progression is getting milder. J Rheumatol (2005) 0.77
Atherosclerotic cardiovascular disease in hospitalized patients with systemic sclerosis: higher mortality than patients with lupus and rheumatoid arthritis. Arthritis Care Res (Hoboken) (2014) 0.77
Unregistered trials are unethical. PLoS Med (2005) 0.75
A short tutorial on item response theory in rheumatology. Clin Exp Rheumatol (2014) 0.75
Vascular disease in systemic sclerosis. Int J Rheumatol (2010) 0.75
National databases and rheumatology research II: the National Health and Nutrition Examination Surveys. Rheum Dis Clin North Am (2004) 0.75
Filipino gout: a review. Arthritis Care Res (Hoboken) (2014) 0.75
Gout and the heart. Rheum Dis Clin North Am (2014) 0.75
Pegloticase and the patient with treatment-failure gout. Expert Rev Clin Pharmacol (2012) 0.75
Systemic sclerosis 2011. Int J Rheumatol (2012) 0.75